Recurrent Bladder Carcinoma: Clinical and Prognostic Role of 18 F-FDG PET/CT

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2016 Aug 28

PMID 27565154

Citations 17

Authors

Pierpaolo Alongi

Federico Caobelli

Roberta Gentile

Alessandro Stefano

Giorgio Russo

Domenico Albano

Sergio Baldari

Maria Carla Gilardi

Massimo Midiri

Affiliations

Soon will be listed here.

Abstract

Aim: A small number of studies evaluated the detection rate of lesions from bladder carcinoma (BC) of 18 F-FDG PET/CT in the restaging process. However, the prognostic role of FDG PET/CT still remains unclear. The aim of the present study was to evaluate the accuracy, the effect upon treatment decision, and the prognostic value of FDG PET/CT in patients with suspected recurrent BC.

Materials And Methods: Forty-one patients affected by BC underwent FDG PET/CT for restaging purpose. The diagnostic accuracy of visually interpreted FDG PET/CT was assessed compared to histology (n = 8), other diagnostic imaging modalities (contrast-enhanced CT in 38/41 patients and MRI in 15/41) and clinical follow-up (n = 41). Semiquantitative PET values (SUVmax, SUVmean, SUL, MTV, TLG) were calculated using a graph-based method. Progression-free survival (PFS) and overall survival (OS) were assessed by using Kaplan-Meier curves. The risk of progression (hazard ratio, HR) was computed by Cox regression analysis by considering all the available variables.

Results: PET was considered positive in 21 of 41 patients. Of these, recurrent BC was confirmed in 20 (95 %). Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of FDG PET/CT were 87 %, 94 %, 95 %, 85 %, 90 %. AUC was 0.9 (95 %IC 0.8-1). Bayesian positive and negative likelihood ratios were 14.5 and 0.13, respectively. FDG PET/CT findings modified the therapeutic approach in 16 patients (modified therapy in 10 PET-positive patients, watch-and-wait in six PET-negative patients). PFS was significantly longer in patients with negative scan vs. those with pathological findings (85 % vs. 24 %, p < 0.05; HR = 12.4; p = 0.001). Moreover, an unremarkable study was associated with a longer OS (88 % vs. 47 % after 2 years and 87 % vs. 25 % after 3 years, respectively, p < 0.05). Standardized uptake value (SUV)max > 6 and total lesion glycolysis (TLG) > 8.5 were recognized as the most accurate thresholds to predict PFS (2-year PFS 62 % for SUVmax < 6 vs. 15 % for SUVmax > 6, p = 0.018; 2-year PFS 66 % for TLG < 8.5 vs. 18 % for TLG > 8.5, p = 0.09).

Conclusion: A very good diagnostic performance for FDG PET/CT was confirmed in patients with suspected recurrent BC. FDG PET/CT allowed for a change in treatment decision in about 40 % of cases and showed an important prognostic value in assessing PFS and OS.

Citing Articles

Nuclear Medicine and Molecular Imaging in Urothelial Cancer: Current Status and Future Directions.

McDonald S, Keane K, Gauci R, Hayne D Cancers (Basel). 2025; 17(2).

PMID: 39858014 PMC: 11763387. DOI: 10.3390/cancers17020232.

Assessing the Performance of 18F-FDG PET/CT in Bladder Cancer: A Narrative Review of Current Evidence.

Bacchiani M, Salamone V, Massaro E, Sandulli A, Mariottini R, Cadenar A Cancers (Basel). 2023; 15(11).

PMID: 37296913 PMC: 10252107. DOI: 10.3390/cancers15112951.

PET Imaging in Bladder Cancer: An Update and Future Direction.

Zhang-Yin J, Girard A, Marchal E, Lebret T, Homo Seban M, Uhl M Pharmaceuticals (Basel). 2023; 16(4).

PMID: 37111363 PMC: 10144644. DOI: 10.3390/ph16040606.

Mycoplasma infection mimicking a malignancy in a waldenstrom macroglobulinemia patient.

Wu J, He D, Yu F, Huang Y, Bian M, Yu C BMC Infect Dis. 2023; 23(1):219.

PMID: 37029352 PMC: 10080790. DOI: 10.1186/s12879-023-08163-6.

Predicting Recurrence of Non-Muscle-Invasive Bladder Cancer: Current Techniques and Future Trends.

Shalata A, Shehata M, van Bogaert E, Ali K, Alksas A, Mahmoud A Cancers (Basel). 2022; 14(20).

PMID: 36291803 PMC: 9599984. DOI: 10.3390/cancers14205019.

References

Barentsz J, Engelbrecht M, Witjes J, de la Rosette J, van der Graaf M . MR imaging of the male pelvis. Eur Radiol. 1999; 9(9):1722-36. DOI: 10.1007/s003300050916. View

Ploeg M, Aben K, Kiemeney L . The present and future burden of urinary bladder cancer in the world. World J Urol. 2009; 27(3):289-93. PMC: 2694323. DOI: 10.1007/s00345-009-0383-3. View

Apolo A, Riches J, Schoder H, Akin O, Trout A, Milowsky M . Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol. 2010; 28(25):3973-8. PMC: 2940395. DOI: 10.1200/JCO.2010.28.7052. View

Babjuk M, Burger M, Zigeuner R, Shariat S, van Rhijn B, Comperat E . EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013; 64(4):639-53. DOI: 10.1016/j.eururo.2013.06.003. View

Kosuda S, Kison P, Greenough R, Grossman H, Wahl R . Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med. 1997; 24(6):615-20. DOI: 10.1007/BF00841398. View

Tahari A, Chien D, Azadi J, Wahl R . Optimum lean body formulation for correction of standardized uptake value in PET imaging. J Nucl Med. 2014; 55(9):1481-4. PMC: 4337860. DOI: 10.2967/jnumed.113.136986. View

Boers-Sonderen M, de Geus-Oei L, Desar I, van der Graaf W, Oyen W, Ottevanger P . Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT. Target Oncol. 2014; 9(4):339-47. DOI: 10.1007/s11523-014-0309-x. View

Liao S, Lan X, Cao G, Yuan H, Zhang Y . Prognostic predictive value of total lesion glycolysis from 18F-FDG PET/CT in post-surgical patients with epithelial ovarian cancer. Clin Nucl Med. 2013; 38(9):715-20. DOI: 10.1097/RLU.0b013e31829f57fa. View

Drieskens O, Oyen R, van Poppel H, Vankan Y, Flamen P, Mortelmans L . FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging. 2005; 32(12):1412-7. DOI: 10.1007/s00259-005-1886-9. View

10.

Caobelli F, Alongi P, Evangelista L, Picchio M, Saladini G, Rensi M . Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study. Eur J Nucl Med Mol Imaging. 2015; 43(3):404-13. DOI: 10.1007/s00259-015-3184-5. View

11.

Maurer T, Horn T, Heck M, Gschwend J, Eiber M, Beer A . Current Staging Procedures in Urinary Bladder Cancer. Diagnostics (Basel). 2016; 3(3):315-24. PMC: 4665464. DOI: 10.3390/diagnostics3030315. View

12.

Boellaard R, ODoherty M, Weber W, Mottaghy F, Lonsdale M, Stroobants S . FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2009; 37(1):181-200. PMC: 2791475. DOI: 10.1007/s00259-009-1297-4. View

13.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30. DOI: 10.3322/caac.21166. View

14.

Stein J, Lieskovsky G, Cote R, Groshen S, Feng A, Boyd S . Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19(3):666-75. DOI: 10.1200/JCO.2001.19.3.666. View

15.

Alongi P, Picchio M, Zattoni F, Spallino M, Gianolli L, Saladini G . Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT. Eur J Nucl Med Mol Imaging. 2015; 43(3):464-73. DOI: 10.1007/s00259-015-3159-6. View

16.

Boellaard R, Delgado-Bolton R, Oyen W, Giammarile F, Tatsch K, Eschner W . FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2014; 42(2):328-54. PMC: 4315529. DOI: 10.1007/s00259-014-2961-x. View

17.

Lu Y, Chen J, Liang J, Wang H, Lin C, Lin W . Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol. 2011; 81(9):2411-6. DOI: 10.1016/j.ejrad.2011.07.018. View

18.

Jadvar H, Quan V, Henderson R, Conti P . [F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. Int J Clin Oncol. 2008; 13(1):42-7. PMC: 2295284. DOI: 10.1007/s10147-007-0720-8. View

19.

Goodfellow H, Viney Z, Hughes P, Rankin S, Rottenberg G, Hughes S . Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer. BJU Int. 2013; 114(3):389-95. DOI: 10.1111/bju.12608. View

20.

Ozturk H, Karapolat I . Efficacy of F-fluorodeoxyglucose-positron emission tomography/computed tomography in restaging muscle-invasive bladder cancer following radical cystectomy. Exp Ther Med. 2015; 9(3):717-724. PMC: 4316965. DOI: 10.3892/etm.2015.2187. View